{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:13:29Z","timestamp":1792620809953,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s10067-024-07142-9","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T08:02:53Z","timestamp":1726819373000},"page":"3525-3536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["JAK inhibitors inhibit angiogenesis by reducing VEGF production from rheumatoid arthritis\u2013derived fibroblast-like synoviocytes"],"prefix":"10.1007","volume":"43","author":[{"given":"Kensuke","family":"Anjiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4308-9845","authenticated-orcid":false,"given":"Shinya","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenmei","family":"Ikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyui","family":"Kamenaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Tsubosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nkano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsumiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"7142_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/S10456-015-9477-2","volume":"18","author":"HA Elshabrawy","year":"2015","unstructured":"Elshabrawy HA, Chen Z, Volin MV et al (2015) The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis 18:433\u2013448. https:\/\/doi.org\/10.1007\/S10456-015-9477-2","journal-title":"Angiogenesis"},{"key":"7142_CR2","doi-asserted-by":"publisher","first-page":"945129","DOI":"10.3389\/fimmu.2022.945129","volume":"13","author":"X Liu","year":"2022","unstructured":"Liu X, Wang Z, Qian H et al (2022) Natural medicines of targeted rheumatoid arthritis and its action mechanism. Front Immunol 13:945129. https:\/\/doi.org\/10.3389\/fimmu.2022.945129","journal-title":"Front Immunol"},{"key":"7142_CR3","doi-asserted-by":"publisher","first-page":"1188835","DOI":"10.3389\/fimmu.2023.1188835","volume":"14","author":"EML Philippon","year":"2023","unstructured":"Philippon EML, van Rooijen LJE, Khodadust F et al (2023) A novel 3D spheroid model of rheumatoid arthritis synovial tissue incorporating fibroblasts, endothelial cells, and macrophages. Front Immunol 14:1188835. https:\/\/doi.org\/10.3389\/fimmu.2023.1188835","journal-title":"Front Immunol"},{"key":"7142_CR4","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023\u20132038. https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"issue":"2","key":"7142_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/med.21990","volume":"44","author":"AT Rufino","year":"2024","unstructured":"Rufino AT, Freitas M, Proen\u00e7a C et al (2024) Rheumatoid arthritis molecular targets and their importance to flavonoid-based therapy. Med Res Rev 44(2):497\u2013538. https:\/\/doi.org\/10.1002\/med.21990","journal-title":"Med Res Rev"},{"key":"7142_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.VPH.2009.02.002","volume":"51","author":"Z Szekanecz","year":"2009","unstructured":"Szekanecz Z, Koch AE (2009) Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol 51:1\u20137. https:\/\/doi.org\/10.1016\/J.VPH.2009.02.002","journal-title":"Vascul Pharmacol"},{"key":"7142_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/35025215","volume":"407","author":"GD Yancopoulos","year":"2000","unstructured":"Yancopoulos GD, Davis S, Gale NW et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242\u2013248. https:\/\/doi.org\/10.1038\/35025215","journal-title":"Nature"},{"key":"7142_CR8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/ART.11143","volume":"48","author":"H Nakahara","year":"2003","unstructured":"Nakahara H, Song J, Sugimoto M et al (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48:1521\u20131529. https:\/\/doi.org\/10.1002\/ART.11143","journal-title":"Arthritis Rheum"},{"key":"7142_CR9","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/S00296-009-0885-8","volume":"29","author":"M Hashizume","year":"2009","unstructured":"Hashizume M, Hayakawa N, Suzuki M, Mihara M (2009) IL-6\/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int 29:1449\u20131454. https:\/\/doi.org\/10.1007\/S00296-009-0885-8","journal-title":"Rheumatol Int"},{"key":"7142_CR10","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1093\/RHEUMATOLOGY\/KES093","volume":"51","author":"K Kayakabe","year":"2012","unstructured":"Kayakabe K, Kuroiwa T, Sakurai N et al (2012) Interleukin-6 promotes destabilized angiogenesis by modulating angiopoietin expression in rheumatoid arthritis. Rheumatology (Oxford) 51:1571\u20131579. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KES093","journal-title":"Rheumatology (Oxford)"},{"issue":"43","key":"7142_CR11","doi-asserted-by":"publisher","first-page":"73529","DOI":"10.18632\/oncotarget.19867","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang J, Li C, Zheng Y et al (2017) Inhibition of angiogenesis by arsenic trioxide via TSP-1-TGF-\u03b21-CTGF-VEGF functional module in rheumatoid arthritis. Oncotarget 8(43):73529\u201373546. https:\/\/doi.org\/10.18632\/oncotarget.19867","journal-title":"Oncotarget"},{"key":"7142_CR12","doi-asserted-by":"publisher","first-page":"751667","DOI":"10.3389\/fphar.2021.751667","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang J, Ma Y, Zhang Y et al (2021) Angiogenesis is inhibited by arsenic trioxide through downregulation of the CircHIPK3\/miR-149-5p\/FOXO1\/VEGF functional module in rheumatoid arthritis. Front Pharmacol 12:751667. https:\/\/doi.org\/10.3389\/fphar.2021.751667","journal-title":"Front Pharmacol"},{"key":"7142_CR13","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMOA1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377\u20132386. https:\/\/doi.org\/10.1056\/NEJMOA1310476","journal-title":"N Engl J Med"},{"key":"7142_CR14","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/ART.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506\u2013517. https:\/\/doi.org\/10.1002\/ART.39953","journal-title":"Arthritis Rheumatol"},{"key":"7142_CR15","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/ANNRHEUMDIS-2019-215164","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Tanaka Y, Tanaka S et al (2019) Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis 78:1305\u20131319. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2019-215164","journal-title":"Ann Rheum Dis"},{"key":"7142_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/ANNRHEUMDIS-2020-218510","volume":"80","author":"SB Cohen","year":"2021","unstructured":"Cohen SB, Van Vollenhoven RF, Winthrop KL et al (2021) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 80:304\u2013311. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2020-218510","journal-title":"Ann Rheum Dis"},{"key":"7142_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/JAMA.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE et al (2019) Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA 322:315. https:\/\/doi.org\/10.1001\/JAMA.2019.9055","journal-title":"JAMA"},{"key":"7142_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/FPED.2018.00230","volume":"6","author":"LA Barreiros","year":"2018","unstructured":"Barreiros LA, Segundo GRS, Grumach AS et al (2018) A novel homozygous JAK3 mutation leading to T-B+NK- SCID in two Brazilian patients. Front Pediatr 6:230. https:\/\/doi.org\/10.3389\/FPED.2018.00230","journal-title":"Front Pediatr"},{"issue":"1","key":"7142_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/S41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M et al (2021) The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 6(1):402. https:\/\/doi.org\/10.1038\/S41392-021-00791-1","journal-title":"Signal Transduct Target Ther"},{"key":"7142_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/J.SEMARTHRIT.2020.10.008","volume":"51","author":"LS Simon","year":"2021","unstructured":"Simon LS, Taylor PC, Choy EH et al (2021) The Jak\/STAT pathway: a focus on pain in rheumatoid arthritis. Semin Arthritis Rheum 51:278\u2013284. https:\/\/doi.org\/10.1016\/J.SEMARTHRIT.2020.10.008","journal-title":"Semin Arthritis Rheum"},{"key":"7142_CR21","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/NRDP.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A et al (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001. https:\/\/doi.org\/10.1038\/NRDP.2018.1","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"7142_CR22","doi-asserted-by":"publisher","first-page":"e0180922","DOI":"10.1371\/JOURNAL.PONE.0180922","volume":"12","author":"KR Gillinder","year":"2017","unstructured":"Gillinder KR, Tuckey H, Bell CC et al (2017) Direct targets of pSTAT5 signalling in erythropoiesis. PLoS One 12(7):e0180922. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0180922","journal-title":"PLoS One"},{"issue":"9","key":"7142_CR23","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.3390\/IJMS22094980","volume":"22","author":"I Roger","year":"2021","unstructured":"Roger I, Milara J, Montero P, Cortijo J (2021) The role of JAK\/STAT molecular pathway in vascular remodeling associated with pulmonary hypertension. Int J Mol Sci 22(9):4980. https:\/\/doi.org\/10.3390\/IJMS22094980","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7142_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/S41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G et al (2021) Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 6(1):263. https:\/\/doi.org\/10.1038\/S41392-021-00658-5","journal-title":"Signal Transduct Target Ther"},{"key":"7142_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ART.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324. https:\/\/doi.org\/10.1002\/ART.1780310302","journal-title":"Arthritis Rheum"},{"key":"7142_CR26","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1136\/ARD.2010.130310","volume":"69","author":"J Funovits","year":"2010","unstructured":"Funovits J, Aletaha D, Bykerk V et al (2010) The 2010 American College of Rheumatology\/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis 69:1589\u20131595. https:\/\/doi.org\/10.1136\/ARD.2010.130310","journal-title":"Ann Rheum Dis"},{"key":"7142_CR27","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1002\/ART.27580","volume":"62","author":"T Neogi","year":"2010","unstructured":"Neogi T, Aletaha D, Silman AJ et al (2010) The 2010 American College of Rheumatology\/European League Against Rheumatism classification criteria for rheumatoid arthritis: phase 2 methodological report. Arthritis Rheum 62:2582\u20132591. https:\/\/doi.org\/10.1002\/ART.27580","journal-title":"Arthritis Rheum"},{"key":"7142_CR28","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/ART.1780310803","volume":"31","author":"M Rooney","year":"1988","unstructured":"Rooney M, Condell D, Quinlan W et al (1988) Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 31:956\u2013963. https:\/\/doi.org\/10.1002\/ART.1780310803","journal-title":"Arthritis Rheum"},{"key":"7142_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/S00296-009-1158-2","volume":"30","author":"H Yamanaka","year":"2010","unstructured":"Yamanaka H, Goto KI, Miyamoto K (2010) Scoring evaluation for histopathological features of synovium in patients with rheumatoid arthritis during anti-tumor necrosis factor therapy. Rheumatol Int 30:409\u2013413. https:\/\/doi.org\/10.1007\/S00296-009-1158-2","journal-title":"Rheumatol Int"},{"key":"7142_CR30","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/ART.21767","volume":"54","author":"D Makrygiannakis","year":"2006","unstructured":"Makrygiannakis D, Af Klint E, Catrina SB et al (2006) Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. Arthritis Rheum 54:1463\u20131472. https:\/\/doi.org\/10.1002\/ART.21767","journal-title":"Arthritis Rheum"},{"key":"7142_CR31","doi-asserted-by":"crossref","unstructured":"Revu S, Nereg\u00e5rd P, af Klint E, Korotkova M, Catrina AI (2013) Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate. Arthritis Res Ther https:\/\/pubmed.ncbi.nlm.nih.gov\/24295447\/. Accessed 22 Jan 2024","DOI":"10.1186\/ar4398"},{"key":"7142_CR32","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"7142_CR33","first-page":"175","volume-title":"Behavior research methods","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. In: Behavior research methods. Psychonomic Society Inc., pp 175\u2013191"},{"key":"7142_CR34","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/ART.11043","volume":"48","author":"J Gentiletti","year":"2003","unstructured":"Gentiletti J, Fava RA (2003) Does vascular endothelial growth factor play a role in interleukin-6 receptor antagonist therapy for rheumatoid arthritis? Arthritis Rheum 48:1471\u20131474. https:\/\/doi.org\/10.1002\/ART.11043","journal-title":"Arthritis Rheum"},{"key":"7142_CR35","doi-asserted-by":"publisher","first-page":"709057","DOI":"10.3389\/fonc.2021.709057","volume":"11","author":"Y Lu","year":"2021","unstructured":"Lu Y, Zhao H, Liu Y et al (2021) Chronic stress activates PlexinA1\/VEGFR2-JAK2-STAT3 in vascular endothelial cells to promote angiogenesis. Front Oncol 11:709057. https:\/\/doi.org\/10.3389\/fonc.2021.709057","journal-title":"Front Oncol"},{"key":"7142_CR36","doi-asserted-by":"publisher","first-page":"102051","DOI":"10.1016\/j.redox.2021.102051","volume":"45","author":"C Hu","year":"2021","unstructured":"Hu C, Wu Z, Huang Z, Hao X et al (2021) Nox2 impairs VEGF-A-induced angiogenesis in placenta via mitochondrial ROS-STAT3 pathway. Redox Biol 45:102051. https:\/\/doi.org\/10.1016\/j.redox.2021.102051","journal-title":"Redox Biol"},{"issue":"1","key":"7142_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/S13075-021-02587-8","volume":"23","author":"P Di Benedetto","year":"2021","unstructured":"Di Benedetto P, Ruscitti P, Berardicurti O et al (2021) Blocking Jak\/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. Arthritis Res Ther 23(1):213. https:\/\/doi.org\/10.1186\/S13075-021-02587-8","journal-title":"Arthritis Res Ther"},{"key":"7142_CR38","doi-asserted-by":"publisher","first-page":"109044","DOI":"10.1016\/J.INTIMP.2022.109044","volume":"110","author":"Y Liu","year":"2022","unstructured":"Liu Y, Hu M, Fan G et al (2022) Effect of baricitinib on the epithelial-mesenchymal transition of alveolar epithelial cells induced by IL-6. Int Immunopharmacol 110:109044. https:\/\/doi.org\/10.1016\/J.INTIMP.2022.109044","journal-title":"Int Immunopharmacol"},{"key":"7142_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/J.JOT.2019.07.007","volume":"22","author":"WX Cheng","year":"2019","unstructured":"Cheng WX, Huang H, Chen JH et al (2019) Genistein inhibits angiogenesis developed during rheumatoid arthritis through the IL-6\/JAK2\/STAT3\/VEGF signalling pathway. J Orthop Translat 22:92\u2013100. https:\/\/doi.org\/10.1016\/J.JOT.2019.07.007","journal-title":"J Orthop Translat"},{"key":"7142_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1167\/IOVS.09-3511","volume":"51","author":"Z Zheng","year":"2010","unstructured":"Zheng Z, Chen H, Zhao H et al (2010) Inhibition of JAK2\/STAT3-mediated VEGF upregulation under high glucose conditions by PEDF through a mitochondrial ROS pathway in vitro. Invest Ophthalmol Vis Sci 51:64\u201371. https:\/\/doi.org\/10.1167\/IOVS.09-3511","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7142_CR41","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1096\/FJ.201701074RR","volume":"32","author":"XP Zhang","year":"2018","unstructured":"Zhang XP, Li KR, Yu Q et al (2018) Ginsenoside Rh2 inhibits vascular endothelial growth factor-induced corneal neovascularization. FASEB J 32:3782\u20133791. https:\/\/doi.org\/10.1096\/FJ.201701074RR","journal-title":"FASEB J"},{"issue":"14","key":"7142_CR42","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.3390\/ijms22147516","volume":"22","author":"E Nigro","year":"2021","unstructured":"Nigro E, Mallardo M, Polito R et al (2021) Adiponectin and leptin exert antagonizing effects on HUVEC tube formation and migration modulating the expression of CXCL1, VEGF, MMP-2 and MMP-9. Int J Mol Sci 22(14):7516. https:\/\/doi.org\/10.3390\/ijms22147516","journal-title":"Int J Mol Sci"},{"key":"7142_CR43","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1007\/S10067-023-06787-2","volume":"42","author":"L Vallez-Valero","year":"2023","unstructured":"Vallez-Valero L, Gas\u00f3-Gago I, Marcos-Fendian \u00c1 et al (2023) Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib. Clin Rheumatol 42:3225\u20133235. https:\/\/doi.org\/10.1007\/S10067-023-06787-2","journal-title":"Clin Rheumatol"},{"key":"7142_CR44","doi-asserted-by":"publisher","first-page":"173238","DOI":"10.1016\/J.EJPHAR.2020.173238","volume":"882","author":"T Emori","year":"2020","unstructured":"Emori T, Kasahara M, Sugahara S et al (2020) Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: effect of the novel JAK inhibitor peficitinib. Eur J Pharmacol 882:173238. https:\/\/doi.org\/10.1016\/J.EJPHAR.2020.173238","journal-title":"Eur J Pharmacol"},{"key":"7142_CR45","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/S40265-017-0835-9","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon S (2017) Tofacitinib: a review in rheumatoid arthritis. Drugs 77:1987\u20132001. https:\/\/doi.org\/10.1007\/S40265-017-0835-9","journal-title":"Drugs"},{"key":"7142_CR46","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/S40265-018-0908-4","volume":"78","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama ZT, Scott LJ (2018) Baricitinib: a review in rheumatoid arthritis. Drugs 78:761\u2013772. https:\/\/doi.org\/10.1007\/S40265-018-0908-4","journal-title":"Drugs"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07142-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07142-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07142-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T05:06:10Z","timestamp":1729227970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07142-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["7142"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07142-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}